Netupitant - Palonosetron Fdc - Global Market Opportunity Assessment Study, 2012 - 2018



Transparency Market Research

$ 3795

In Stock

This report covers Netupitant - Palonosetron FDC along with their sales projection, current scenario, SWOT analysis, clinical trials and opportunities. It also covers the factors driving this market and the regional analysis including United States, Europe, Australia and UK among others.  The present market condition and performance has been mentioned in detail along with the CINV patient pool. Moreover, the report provides in-depth analysis of Netupitant - Palonosetron FDC market with their estimated and forecast market size till 2018.

The global Chemotherapy-induced nausea and vomiting (CINV) market is expected to reach USD 1.7 billion by 2015, due to prevalent cancer related conditions and subsequent increase in CINV pool. The global CINV patient pool is estimated to reach 4.6 million by 2015 and the Asian region is expected to witness largest patient share for CINV contributing majorly to the total CINV patient pool. Therefore, Asian market is expected have huge potential in the Netupitant - Palonosetron market.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with key opinion leaders. This research is specially designed to estimate and analyze the performance of Netupitant-Palonosetron FDC in global scenario. This research provides in-depth analysis of Netupitant-Palonosetron FDC market sales, trend analysis by segments and demand by geography. The in-depth research and high level analysis will allow Netupitant-Palonosetron FDC players to make informed decisions about Netupitant-Palonosetron FDC market in the present and future scenario.
Table of Content

1. Preface
1.1. Report Description
1.2. Research Methodology
1.1.1. Therapeutic Classes
1.1.2. Order of Entry into the Market
1.1.3. Indications
1.1.4. Dosage & Formulation Type
1.1.1. Company Overview
1.1.2. Business Strategy
1.1.3. Financial Overview
1.1.4. Products and Services
1.1.5. Recent Developments

2. Executive Summary and Market Overview

3. Market Analysis
3.1. Introduction: Chemotherapy Induced Nausea and Vomiting (CINV)
3.1.1. Description
3.1.2. Aetiology/Causes for CINV 
3.1.3. Current Drug Treatment Available 
3.2. CINV Market Size & Opportunity Scenario (1/2)
3.2.1. Global CINV Market (USD Million), 2009 - 2015 
3.2.2. CINV Market (USD Million), by Geography, 2009 – 2015
3.2.3. Global CINV Patient Pool (Million), 2009 – 2015
3.2.4. CINV Target Patient Pool, by Geography, 2009 - 2015
3.3. Description of Netupitant - Palonosetron FDC 
3.4. Mechanism of Action of Netupitant - Palonosetron FDC 
3.5. Clinical Trials Detail 
3.5.1. Clinical Trial Detail – 1 Trials Id - NCT01376297 
3.5.2. Clinical Trial Detail – 2 Trials Id - NCT01339260 
3.6. Unmet Needs in CINV Market 
3.7. Factors influential to the sales of Netupitant - Palonosetron FDC 
3.8. Sales Projection: Netupitant - Palonosetron FDC 
3.8.1. Global Target Patient Pool 
3.8.2. Global Forecasted Sales in $ in 000's
3.9. SWOT Analysis 
3.9.1. Strength
3.9.2. Weakness
3.9.3. Opportunity
3.9.4. Threat
3.10. Overall License Agreement for Netupitant - Palonosetron FDC
3.10.1. Global
3.10.2. United States
3.10.3. Europe
3.10.4. Australia
3.10.5. UK & Ireland
3.10.6. South Korea
3.11. Company Profile – Helsinn Group